STI571: Targeting BCR-ABL as Therapy for CML

STI571: Targeting BCR-ABL as Therapy for CML Michael J. Mauro, Brian J. Druker Oncologist 2001; 6: 233-238 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Understand the molecular pathogenesis of chronic myelogenous leukemia. Appreciate how targeted drug development will become increasingly important in cancer medicine. Understand the mechanism of action, toxicities, and pharmacology of STI571, a new anticancer drug directed at a specific molecular target. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 13, 2002 Most Recent Review: Nov. 15, 2005* Most Recent Update: Feb. 13, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.